Statement: Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41.
Primary_evidence: Adverse Events 1:   Total: 83/680 (12.21%)   Hemoglobin 11/680 (1.62%)   Transfusion: Platelets 0/680 (0.00%)   Transfusion: pRBCs 0/680 (0.00%)   Febrile neutropenia 49/680 (7.21%)   Edema 1/680 (0.15%)   Ischemia/infarction 0/680 (0.00%)   Palpitations 0/680 (0.00%)   Pericardial effusion 0/680 (0.00%)   Keratitis 1/680 (0.15%)   Double vision 1/680 (0.15%)   Colitis 1/680 (0.15%) Adverse Events 2:   Total: 86/688 (12.50%)   Hemoglobin 15/688 (2.18%)   Transfusion: Platelets 1/688 (0.15%)   Transfusion: pRBCs 1/688 (0.15%)   Febrile neutropenia 41/688 (5.96%)   Edema 0/688 (0.00%)   Ischemia/infarction 0/688 (0.00%)   Palpitations 1/688 (0.15%)   Pericardial effusion 1/688 (0.15%)   Keratitis 0/688 (0.00%)   Double vision 0/688 (0.00%)   Colitis 0/688 (0.00%)